RxDoctor Payments Data

Shane Manalang

Physician Assistant · Huntington Beach, CANPI 1558648550

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 100 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$562
  • Otsuka America Pharmaceutical, Inc.$314
  • Alkermes, Inc.$312
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$191
  • Teva Pharmaceuticals USA, Inc.$154
  • AbbVie$103
  • plus $383 from 9 others

What the payments were for

  • Food & beverage$1,97398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$2,088,294
Medicare patients
4,759
Services billed
26,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate903$7,043,532
Invega SustennaPaliperidone Palmitate229$651,057
Aripiprazole OdtAripiprazole198$204,113
AristadaAripiprazole Lauroxil35$117,350
Olanzapine OdtOlanzapine592$99,506
Abilify MaintenaAripiprazole25$70,028
Risperidone OdtRisperidone280$61,440
Aripiprazole412$39,795
RexultiBrexpiprazole22$31,501
Quetiapine Fumarate1,301$31,201
PerserisRisperidone12$31,196
Paliperidone ErPaliperidone135$26,979
VraylarCariprazine Hcl23$22,354
Divalproex Sodium702$21,638
Haloperidol360$17,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$562$651,057229 claims
Alkermes, Inc.Aristada$312$117,35035 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$314$101,52947 claims
Indivior Inc.Perseris$55$31,19612 claims
AbbVieVraylar$103$22,35423 claims
Almatica Pharma LLCSertraline Hcl$86$3,073292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Huntington Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →